glp-1 good or bad Do The Benefits of Drugs OutWeigh the Negatives? GLP-1 therapies are changing obesity

The selective inhibitor compound 27 (IPN60090), which is currently in a first-in-class clinical trial, focuses on optimising physicochemical and pharmacokinetic properties, with a strong in vivo target engagement capability, and should strongly inhibit GLS in humans [152, 153]

Vitamin B12 deficiency left untreated can lead to pernicious anaemia or neurological problems

We're here to support you

Instead, clinicians should acknowledge this risk and consider individualized risk-benefit strategies when prescribing GLP-1 RAs, particularly for patients with pre-existing ocular manifestations and must inform patients regarding possible ocular hazards while advocating for regular retinal examinations and assessments of visual acuity

While this higher bioavailability is excellent for efficiency, it also means you need to be more mindful of your dosage